PL3275871T3 - Kryształy - Google Patents
KryształyInfo
- Publication number
- PL3275871T3 PL3275871T3 PL17186415T PL17186415T PL3275871T3 PL 3275871 T3 PL3275871 T3 PL 3275871T3 PL 17186415 T PL17186415 T PL 17186415T PL 17186415 T PL17186415 T PL 17186415T PL 3275871 T3 PL3275871 T3 PL 3275871T3
- Authority
- PL
- Poland
- Prior art keywords
- crystals
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
- C07D241/22—Benzenesulfonamido pyrazines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D241/20—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Reproductive Health (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Gynecology & Obstetrics (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2009151728 | 2009-06-26 | ||
| JP2009151729 | 2009-06-26 | ||
| JP2009151727 | 2009-06-26 | ||
| PCT/JP2010/060798 WO2010150865A1 (ja) | 2009-06-26 | 2010-06-25 | 結晶 |
| EP17186415.0A EP3275871B1 (en) | 2009-06-26 | 2010-06-25 | Crystals |
| EP10792183.5A EP2447254B1 (en) | 2009-06-26 | 2010-06-25 | Crystals |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3275871T3 true PL3275871T3 (pl) | 2020-07-27 |
Family
ID=43386634
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL10792183T PL2447254T3 (pl) | 2009-06-26 | 2010-06-25 | Kryształy |
| PL17186415T PL3275871T3 (pl) | 2009-06-26 | 2010-06-25 | Kryształy |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL10792183T PL2447254T3 (pl) | 2009-06-26 | 2010-06-25 | Kryształy |
Country Status (33)
| Country | Link |
|---|---|
| US (4) | US8791122B2 (pl) |
| EP (3) | EP3689855A1 (pl) |
| JP (1) | JPWO2010150865A1 (pl) |
| KR (5) | KR20250107951A (pl) |
| CN (2) | CN104326991A (pl) |
| AR (1) | AR077242A1 (pl) |
| AU (1) | AU2010263569B2 (pl) |
| BR (2) | BRPI1015936B1 (pl) |
| CA (1) | CA2764475C (pl) |
| CL (1) | CL2011003264A1 (pl) |
| CO (1) | CO6430432A2 (pl) |
| CY (3) | CY1119788T1 (pl) |
| DK (2) | DK3275871T3 (pl) |
| ES (2) | ES2660007T3 (pl) |
| HR (2) | HRP20180171T1 (pl) |
| HU (3) | HUE036721T2 (pl) |
| IL (3) | IL216928A (pl) |
| LT (3) | LT3275871T (pl) |
| MA (1) | MA33637B1 (pl) |
| MX (2) | MX346318B (pl) |
| MY (1) | MY186531A (pl) |
| NO (2) | NO2447254T3 (pl) |
| NZ (1) | NZ597352A (pl) |
| PH (2) | PH12015502825A1 (pl) |
| PL (2) | PL2447254T3 (pl) |
| PT (2) | PT3275871T (pl) |
| RU (1) | RU2556206C3 (pl) |
| SG (2) | SG10201403313WA (pl) |
| SI (2) | SI2447254T1 (pl) |
| SM (2) | SMT201800077T1 (pl) |
| TW (1) | TWI531565B (pl) |
| WO (1) | WO2010150865A1 (pl) |
| ZA (1) | ZA201109099B (pl) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104761509A (zh) * | 2008-02-28 | 2015-07-08 | 日本新药株式会社 | 纤维化抑制剂 |
| JP5609643B2 (ja) * | 2008-07-23 | 2014-10-22 | 東レ株式会社 | 慢性腎不全処置剤 |
| CN106279047B (zh) * | 2015-05-13 | 2019-05-03 | 普济生物科技（台州）有限公司 | 一种前列环素受体激动剂的制备方法 |
| WO2016193994A1 (en) | 2015-05-29 | 2016-12-08 | Megafine Pharma (P) Ltd. | Amorphous selexipag and process for preparation thereof |
| WO2017029594A1 (en) * | 2015-08-17 | 2017-02-23 | Dr. Reddy's Laboratories Limited | Processes for preparation of selexipag and its amorphous form |
| US10188648B2 (en) | 2015-09-03 | 2019-01-29 | Teva Pharmaceuticals International Gmbh | Solid state forms of selexipag |
| WO2017042731A1 (en) | 2015-09-10 | 2017-03-16 | Lupin Limited | Amorphous form of selexipag and solid dispersion thereof |
| WO2017042828A2 (en) * | 2015-09-10 | 2017-03-16 | Megafine Pharma (P) Ltd. | Process for the preparation of selexipag and intermediates thereof |
| BR112018009534B1 (pt) * | 2015-12-02 | 2023-11-07 | Nippon Shinyaku Co., Ltd | Composição farmacêutica contendo 2-{4-[n-(5,6-difenilpirazin-2-il)-nisopropilamino]butiloxi }-n-(metilsulfonil)acetamida |
| WO2017109772A1 (en) * | 2015-12-20 | 2017-06-29 | Mapi Pharma Ltd. | Amorphous form of selexipag |
| EP3192502A1 (en) | 2016-01-15 | 2017-07-19 | Sandoz Ag | Pharmaceutical composition of selexipag |
| EP3436439B1 (en) | 2016-04-01 | 2022-02-16 | Honour (R&D) | Process for the preparation of diphenylpyrazine derivatives |
| CN105949135A (zh) * | 2016-05-10 | 2016-09-21 | 湖南欧亚生物有限公司 | 一种赛乐西帕的合成方法 |
| WO2018008042A1 (en) * | 2016-07-05 | 2018-01-11 | Maithri Drugs Private Limited | Novel process for the preparation of 2-{4-[(5,6-diphenyl pyrazin-2-yl)(isopropyl)amino]butoxy}-n-(methylsulfonyl)acetamide and novel polymorphs thereof |
| WO2018015974A1 (en) | 2016-07-20 | 2018-01-25 | Mylan Laboratories Limited | Polymorphic forms and amorphous solid dispersion of selexipag |
| WO2018022704A1 (en) | 2016-07-26 | 2018-02-01 | Teva Pharmaceuticals International Gmbh | Crystalline form vi of selexipag |
| WO2018078383A1 (en) | 2016-10-27 | 2018-05-03 | Cipla Limited | Pharmaceutical composition comprising amorphous selexipag |
| CN108069914A (zh) * | 2016-11-17 | 2018-05-25 | 江苏艾立康药业股份有限公司 | 一种西里帕格晶型的制备方法 |
| RU2019121646A (ru) | 2016-12-14 | 2021-01-15 | Респира Терапьютикс, Инк. | Способы и композиции для лечения легочной гипертензии и других заболеваний легких |
| EP3335699A1 (en) | 2016-12-15 | 2018-06-20 | H e x a l Aktiengesellschaft | Selexipag formulation in liquisolid system |
| JOP20190204A1 (ar) | 2017-03-08 | 2019-09-05 | Actelion Pharmaceuticals Ltd | تركيبة صيدلانية تشتمل على سيليكسيباغ |
| MX2020000999A (es) | 2017-07-27 | 2020-07-22 | Allergan Inc | Agonistas del receptor de prostacyclin para reducir la grasa corporal. |
| AU2018338856B2 (en) * | 2017-09-28 | 2023-09-21 | Nippon Shinyaku Co., Ltd. | Crystal |
| AU2018369664A1 (en) * | 2017-11-16 | 2020-05-21 | Nippon Shinyaku Co., Ltd. | Controlled release formulation |
| US10407396B2 (en) | 2017-11-16 | 2019-09-10 | Apotex Inc. | Crystalline form of selexipag |
| WO2019154363A1 (zh) | 2018-02-07 | 2019-08-15 | 南京明德新药研发有限公司 | 前列环素受体受体激动剂 |
| SG11202007967YA (en) * | 2018-02-21 | 2020-09-29 | Nippon Shinyaku Co Ltd | Granular composition, production method for granular composition, and dissolution property improvement method for granular composition |
| CN109125325B (zh) | 2018-09-25 | 2021-05-25 | 中国人民解放军总医院 | 前列环素受体激动剂的医药用途 |
| US12427145B2 (en) | 2019-02-03 | 2025-09-30 | Innovate Therapeutics Llc | Controlled release pharmaceutical composition of Selexipag or it's active metabolite |
| EP3705115B1 (en) | 2019-03-07 | 2021-06-30 | Alfred E. Tiefenbacher (GmbH & Co. KG) | Composition containing selexipag |
| US20220331313A1 (en) | 2019-05-06 | 2022-10-20 | Actelion Pharmaceuticals Ltd | Methods for treating sarcoidosis-associated pulmonary hypertension |
| JP2022533394A (ja) | 2019-05-21 | 2022-07-22 | アクテリオン ファーマシューティカルズ リミテッド | 肺動脈性肺高血圧症の治療を受けている患者のセレキシパグへの移行方法 |
| WO2020249602A1 (en) | 2019-06-11 | 2020-12-17 | Actelion Pharmaceuticals Ltd | Methods for treating pulmonary arterial hypertension |
| WO2021023271A1 (zh) * | 2019-08-06 | 2021-02-11 | 南京明德新药研发有限公司 | 作为前列环素受体激动剂的化合物的晶型及其制备方法 |
| AU2020369912A1 (en) | 2019-10-23 | 2022-04-14 | Actelion Pharmaceuticals Ltd | Pharmaceutical composition comprising selexipag |
| BR112022010311A2 (pt) | 2019-11-29 | 2022-08-16 | Actelion Pharmaceuticals Ltd | Métodos de tratamento de hipertensão arterial pulmonar |
| AU2020408323A1 (en) | 2019-12-16 | 2022-08-11 | Tenax Therapeutics, Inc. | Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (PH-HF-pEF) |
| US20230113077A1 (en) | 2020-01-31 | 2023-04-13 | Actelion Pharmaceuticals Ltd | Controlled release selexipag composition |
| EP4100013A1 (en) | 2020-02-03 | 2022-12-14 | Actelion Pharmaceuticals Ltd | Methods of treating and assessing pulmonary arterial hypertension with selexipag |
| CN112500358B (zh) * | 2020-11-18 | 2022-03-15 | 江苏豪森药业集团有限公司 | 赛乐西帕晶型及其制备方法 |
| WO2022106621A1 (en) | 2020-11-20 | 2022-05-27 | Actelion Pharmaceuticals Ltd | Selexipag for use via intracolonic administration |
| TW202241425A (zh) | 2021-01-29 | 2022-11-01 | 瑞士商艾克泰聯製藥有限公司 | 用於製造二苯基吡𠯤衍生物之程序 |
| TW202239408A (zh) | 2021-01-29 | 2022-10-16 | 瑞士商艾克泰聯製藥有限公司 | 包含二苯基吡𠯤衍生物的醫藥組成物 |
| WO2022238375A1 (en) | 2021-05-11 | 2022-11-17 | Actelion Pharmaceuticals Ltd | Methods of treating pulmonary hypertension |
| US20250064799A1 (en) | 2021-12-31 | 2025-02-27 | Tenax Therapeutics, Inc. | Oral formulations of levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction |
| WO2023131608A1 (en) | 2022-01-04 | 2023-07-13 | Actelion Pharmaceuticals Ltd | Controlled release compositions |
| WO2023214059A1 (en) | 2022-05-06 | 2023-11-09 | Actelion Pharmaceuticals Ltd | Diphenylpyrazine compounds as prodrugs |
| WO2024017964A1 (en) | 2022-07-20 | 2024-01-25 | Actelion Pharmaceuticals Ltd | Injectable pharmaceutical composition comprising a diphenylpyrazine derivative |
| WO2024133620A1 (en) | 2022-12-22 | 2024-06-27 | Actelion Pharmaceuticals Ltd | In vitro dissolution test |
| WO2024142718A1 (ja) * | 2022-12-27 | 2024-07-04 | 株式会社トクヤマ | セレキシパグのｉ型結晶の製造方法 |
| EP4393475A1 (en) | 2022-12-28 | 2024-07-03 | Sanovel Ilac Sanayi Ve Ticaret A.S. | Formulations comprising selexipag |
| EP4393476A1 (en) * | 2022-12-28 | 2024-07-03 | Sanovel Ilac Sanayi Ve Ticaret A.S. | A tablet formulation comprising selexipag |
| EP4393474A1 (en) | 2022-12-28 | 2024-07-03 | Sanovel Ilac Sanayi Ve Ticaret A.S. | A formulation comprising selexipag |
| TW202444370A (zh) | 2023-03-23 | 2024-11-16 | 瑞士商艾克泰聯製藥有限公司 | 包含二苯基吡衍生物之醫藥組成物 |
| WO2025196095A1 (en) | 2024-03-20 | 2025-09-25 | Actelion Pharmaceuticals Ltd | Injectable pharmaceutical composition for treating pulmonary hypertension |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030092760A1 (en) | 2001-03-12 | 2003-05-15 | Toray Industries, Inc. | Therapeutic agent for renal failure |
| WO2000067748A1 (fr) | 1999-05-10 | 2000-11-16 | Toray Industries, Inc. | Remèdes à l'insuffisance rénale |
| ES2211738T3 (es) | 2000-08-03 | 2004-07-16 | Pfizer Products Inc. | Derivados de diazabiciclooctano y sus usos terapeuticos. |
| US20040116530A1 (en) * | 2001-04-18 | 2004-06-17 | Noriaki Maeda | Tissue fibrosis inhibitors |
| TWI316055B (pl) | 2001-04-26 | 2009-10-21 | Nippon Shinyaku Co Ltd | |
| WO2005000316A1 (ja) | 2003-06-25 | 2005-01-06 | Cardiovascular Institute, Ltd. | 性交機能改善用外用製剤 |
| US7112393B2 (en) | 2003-07-29 | 2006-09-26 | Canon Kabushiki Kaisha | Non-magnetic toner |
| CN104761509A (zh) | 2008-02-28 | 2015-07-08 | 日本新药株式会社 | 纤维化抑制剂 |
| WO2009154246A1 (ja) | 2008-06-19 | 2009-12-23 | 日本新薬株式会社 | 勃起不全治療剤 |
| WO2009157397A1 (ja) | 2008-06-23 | 2009-12-30 | 日本新薬株式会社 | 非ステロイド性抗炎症剤投与に伴う腸管傷害治療剤 |
| KR101639821B1 (ko) | 2008-06-23 | 2016-07-14 | 니뽄 신야쿠 가부시키가이샤 | 염증성 장질환 치료제 |
| SI2292231T1 (sl) | 2008-06-23 | 2016-03-31 | Nippon Shinyaku Co., Ltd. | Terapevtsko sredstvo za stenozo spinalnega kanala |
| JP5609643B2 (ja) | 2008-07-23 | 2014-10-22 | 東レ株式会社 | 慢性腎不全処置剤 |
| ES2522971T3 (es) | 2008-09-10 | 2014-11-19 | Asahi Glass Company, Limited | Nuevo derivado de la prostaglandina I2 |
-
2010
- 2010-06-25 BR BRPI1015936-3A patent/BRPI1015936B1/pt active IP Right Grant
- 2010-06-25 SM SM20180077T patent/SMT201800077T1/it unknown
- 2010-06-25 EP EP19219098.1A patent/EP3689855A1/en active Pending
- 2010-06-25 CN CN201410524475.0A patent/CN104326991A/zh active Pending
- 2010-06-25 PT PT171864150T patent/PT3275871T/pt unknown
- 2010-06-25 US US13/379,531 patent/US8791122B2/en active Active
- 2010-06-25 LT LTEP17186415.0T patent/LT3275871T/lt unknown
- 2010-06-25 AU AU2010263569A patent/AU2010263569B2/en active Active
- 2010-06-25 TW TW099120927A patent/TWI531565B/zh active
- 2010-06-25 SG SG10201403313WA patent/SG10201403313WA/en unknown
- 2010-06-25 JP JP2011519943A patent/JPWO2010150865A1/ja active Pending
- 2010-06-25 RU RU2012102678A patent/RU2556206C3/ru active Protection Beyond IP Right Term
- 2010-06-25 SI SI201031634T patent/SI2447254T1/en unknown
- 2010-06-25 KR KR1020257021877A patent/KR20250107951A/ko active Pending
- 2010-06-25 SM SM20200177T patent/SMT202000177T1/it unknown
- 2010-06-25 WO PCT/JP2010/060798 patent/WO2010150865A1/ja not_active Ceased
- 2010-06-25 KR KR1020177005424A patent/KR20170024165A/ko not_active Ceased
- 2010-06-25 DK DK17186415.0T patent/DK3275871T3/da active
- 2010-06-25 HU HUE10792183A patent/HUE036721T2/hu unknown
- 2010-06-25 HU HUE17186415A patent/HUE048467T2/hu unknown
- 2010-06-25 NZ NZ597352A patent/NZ597352A/xx unknown
- 2010-06-25 ES ES10792183.5T patent/ES2660007T3/es active Active
- 2010-06-25 MY MYPI2011006259A patent/MY186531A/en unknown
- 2010-06-25 DK DK10792183.5T patent/DK2447254T3/en active
- 2010-06-25 EP EP17186415.0A patent/EP3275871B1/en not_active Revoked
- 2010-06-25 KR KR1020127000526A patent/KR102669213B1/ko active Active
- 2010-06-25 HR HRP20180171TT patent/HRP20180171T1/hr unknown
- 2010-06-25 CN CN201080028176.8A patent/CN102459198B/zh active Active
- 2010-06-25 SI SI201031997T patent/SI3275871T1/sl unknown
- 2010-06-25 PT PT107921835T patent/PT2447254T/pt unknown
- 2010-06-25 MX MX2015003876A patent/MX346318B/es unknown
- 2010-06-25 PL PL10792183T patent/PL2447254T3/pl unknown
- 2010-06-25 NO NO10792183A patent/NO2447254T3/no unknown
- 2010-06-25 LT LTEP10792183.5T patent/LT2447254T/lt unknown
- 2010-06-25 BR BR122021005510-6A patent/BR122021005510B1/pt not_active IP Right Cessation
- 2010-06-25 ES ES17186415T patent/ES2797124T3/es active Active
- 2010-06-25 PL PL17186415T patent/PL3275871T3/pl unknown
- 2010-06-25 KR KR1020247016901A patent/KR102705198B1/ko active Active
- 2010-06-25 KR KR1020247016902A patent/KR102829415B1/ko active Active
- 2010-06-25 CA CA2764475A patent/CA2764475C/en active Active
- 2010-06-25 MX MX2011013471A patent/MX2011013471A/es active IP Right Grant
- 2010-06-25 EP EP10792183.5A patent/EP2447254B1/en active Active
- 2010-06-25 AR ARP100102270A patent/AR077242A1/es not_active Application Discontinuation
- 2010-06-25 SG SG2011094083A patent/SG176915A1/en unknown
-
2011
- 2011-12-09 ZA ZA2011/09099A patent/ZA201109099B/en unknown
- 2011-12-13 IL IL216928A patent/IL216928A/en active IP Right Grant
- 2011-12-22 CL CL2011003264A patent/CL2011003264A1/es unknown
- 2011-12-26 CO CO11178426A patent/CO6430432A2/es not_active Application Discontinuation
-
2012
- 2012-01-20 MA MA34554A patent/MA33637B1/fr unknown
-
2014
- 2014-01-22 US US14/160,641 patent/US9284280B2/en active Active
- 2014-01-22 US US14/160,699 patent/US9340516B2/en active Active
-
2015
- 2015-06-09 US US14/734,012 patent/US9440931B2/en active Active
- 2015-12-18 PH PH12015502825A patent/PH12015502825A1/en unknown
- 2015-12-18 PH PH12015502824A patent/PH12015502824A1/en unknown
- 2015-12-27 IL IL243287A patent/IL243287B/en active IP Right Grant
- 2015-12-27 IL IL243293A patent/IL243293A0/en unknown
-
2018
- 2018-01-18 CY CY20181100063T patent/CY1119788T1/el unknown
- 2018-04-11 HU HUS1800015C patent/HUS1800015I1/hu unknown
- 2018-04-11 CY CY2018011C patent/CY2018011I1/el unknown
- 2018-04-18 LT LTPA2018008C patent/LTC2447254I2/lt unknown
- 2018-04-23 NO NO2018015C patent/NO2018015I1/no unknown
-
2020
- 2020-04-02 HR HRP20200539TT patent/HRP20200539T1/hr unknown
- 2020-04-03 CY CY20201100317T patent/CY1122893T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LTC2447254I2 (lt) | Kristalai | |
| BRPI1008774A2 (pt) | espiroamida substituída | |
| DK2414015T3 (da) | Laryngoskopsystem | |
| DK2411442T4 (da) | Umættet polyesterresin | |
| DE112010004215A5 (de) | Hydrostataktor | |
| DE112010002949A5 (de) | Kupplungstastpunkte | |
| EP2445547A4 (en) | CATHETERISM SYSTEM | |
| EP2491340A4 (en) | TELEMETRY PHOTOGRAPHIC APPARATUS | |
| EP2509489A4 (en) | SPRINKLER FOR EARLY HEEL REMOVAL | |
| EP2440486A4 (en) | CABLE RETRACTION SYSTEM | |
| DK2430035T3 (da) | Uracylspipooxetannukleosider | |
| DE112010002728A5 (de) | Turboinhalator | |
| DE112010004249A5 (de) | Spindelaktor | |
| DE112009005323A5 (de) | Hebelarmprüfmaschine | |
| BR112012004964A2 (pt) | girocóptero | |
| BRPI1008070A2 (pt) | tricianoboratos | |
| IT1393701B1 (it) | Rampone | |
| DK2483126T3 (da) | Skinnekøretøj | |
| DE112010004865T8 (de) | Lamellennassreibkupplung | |
| DK2506968T3 (da) | Faujasit-zeolit | |
| EP2454221A4 (en) | cineole | |
| DE112010003255A5 (de) | Fördergutverteiler | |
| BRPI1010159A2 (pt) | bistuti | |
| EP2518828A4 (en) | Rfid tag | |
| EP2448583A4 (en) | Substituted 4-hydroxypyrimidine-5-carboxamides |